Pricing Log in Create free account

Brainstorm Cell Therapeutics Inc. (BCLI) vs Ensysce Biosciences, Inc. (ENSC)

Brainstorm Cell Therapeutics Inc. and Ensysce Biosciences, Inc. are both Biotechnology companies. Brainstorm Cell Therapeutics Inc. and Ensysce Biosciences, Inc. are of similar size ($7.0M and $7.0M). Brainstorm Cell Therapeutics Inc. has the higher net margin (0.00% vs −280.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Brainstorm Cell Therapeutics Inc. leads on 8 and Ensysce Biosciences, Inc. on 4.

Valuation

Metric BCLI ENSC Biotechnology median
P/E n/m n/m 10.60
P/S n/m 0.98 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 1.01 9.02
Earnings yield (103.48%) (811.76%) (32.88%)
Free cash flow yield (40.91%) (199.80%) (23.13%)

Profitability

Metric BCLI ENSC Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% (281.32%) 0.00%
Net margin 0.00% (280.49%) 0.00%
Free cash flow margin 0.00% (196.76%) 0.00%
Return on equity 119.20% (1,295.01%) (51.96%)
Return on assets (627.43%) (295.92%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BCLI ENSC Biotechnology median
Revenue growth (TTM) — (39.29%) 6.76%
EPS growth (last fiscal year) 51.95% 65.24% 29.88%
Revenue growth, 5-year CAGR — 5.21% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCLI ENSC Biotechnology median
Debt to equity (0.11) 0.00 0.00
Current ratio 0.03 0.70 4.97
Net debt to EBITDA (0.10) 0.42 1.01

Dividend

Metric BCLI ENSC Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BCLI ENSC Biotechnology median
Market cap 6.99m 7.02m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack